The global burden of pneumococcal diseases is high, with young children and adults C50 years of age at highest risk of infection. Two types of vaccine are available for the prevention of
. The first pneumococcal conjugate vaccine (PCV7) was licensed in 2000 for immunization against pneumococcal diseases, including sepsis, meningitis, pneumonia, bacteremia, and acute otitis media (AOM) caused by the seven serotypes contained in the vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F) in infants and children aged 2 months to 5 years [3] . PCV10
(serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F) was approved in 2009 for protection against invasive pneumococcal disease (IPD), pneumonia, and AOM in infants and children aged from 6 weeks up to 5 years [4] . A highervalent PCV, PCV13, comprising six additional serotypes to PCV7 (serotypes 1, 3, 5, 6A, 7F, and 19A) is now available in Europe for the prevention of IPD in adults aged C18 years, and for the prevention of IPD, pneumonia, and AOM in infants and children aged between 6 weeks and 17 years [5] .
The global burden of pneumococcal diseases is high, with young children and adults C50 years of age at particular risk of infection. In the 1990s, the age groups with the highest incidence of IPD and highest case fatality rates were infants aged \2 years and adults aged [50 years [6] . Routine childhood pneumococcal immunization programs have helped to alleviate the burden of disease in children [7, 8] . Since 2006, the World Health Organization (WHO) has recommended that PCV be included in all routine childhood immunization programs [9] . Consequently, PCV use has increased from 1% of all WHO member states in 2000 to 44% in 2012, representing 31% of the global birth cohort [9] . Of the European region member states, 49% had introduced PCV by 2012 [9] . Over time the benefits of childhood vaccination with PCV in countries with high uptake have extended to unvaccinated children and adults as a result of the herd effect [10] [11] [12] [13] . However, despite pneumococcal immunization programs covering adults and children, the burden in adults has remained high [14] .
Recommendations for pneumococcal immunization across Europe are complex and are regularly updated. however, many countries have now included PCV in their pneumococcal immunization recommendations for certain groups of children and adults, either alone or in addition to PPV23. Figure 1 details the current adult national recommendations and reimbursement of PCV13.
Age-Based Elements of Pneumococcal

Immunization Programs
Age-based recommendations (usually for older adults) form part of the full immunization programs across most countries in Western Europe. However, the recommended vaccine and the age group eligible for vaccination vary between countries (Table 1) [20] . Although it is too early to assess the longterm impact of the inclusion of PCV in adult immunization programs, estimations can be made based on impact data from PCV7 childhood immunization programs, which have substantially reduced the burden of pneumococcal diseases in children [7, 8] .
Emerging impact data in children show a decline in IPD due to serotypes contained in PCV13, following the introduction of PCV13 in Spain, England, and Norway [21-23].
Furthermore, it is anticipated that PCV13 will be cost-effective. Cost-effectiveness studies have predicted net savings of 102 million 
